MDXG

Business Context and Reporting Period

Company: MiMedx Group, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Status: Development Stage Enterprise
Overview: MiMedx is a musculoskeletal products company operating in three divisions: MiMedx (soft-tissue reconstruction), SpineMedica (spine products), and Level Orthopedics (extremity implants). The company has generated no operating revenue since inception and relies on financing to fund research and development (R&D) and regulatory efforts. The company received FDA 510(k) clearance for its "Paradís Vaso Shield" product in April 2009.

Key Financial Metrics

Debt: As of June 30, 2009, the company held long-term convertible debt with a face value of $3,472,000 (net carrying value $2,841,147). This debt was issued in April-June 2009 at 3% interest, convertible at $0.50 per share.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately 49% (from $3.15M to $1.60M) compared to the same period in 2008, driven by significant cost-cutting measures.
• Operating Expenses:
  • R&D Expenses: Decreased 18.9% to $773,517. While internal personnel costs increased due to hiring, external consultant fees dropped 52.7% and supplies decreased 43.3%.
  • G&A Expenses: Decreased 40.3% to $1,334,316. This reduction was driven by a 53.6% drop in salaries/benefits (due to management resignations and reduced headcount) and a 43.5% drop in professional fees.
• Unusual Items: The company recognized a gain on settlement of payables of $564,838 related to the negotiation and write-off of legal expenses incurred in the prior fiscal year.
• Liquidity: Cash balances increased significantly from $34,828 at March 31, 2009, to $1,620,900 at June 30, 2009, primarily due to the convertible debt offering.

Guidance, Outlook, Risks, and Contingencies

• Liquidity and Going Concern: Management states the company has sufficient funds to operate only through mid-September 2009 without additional financing. The ability to continue as a going concern is dependent on securing additional capital.
• Financing Plans: The company is considering a PIPE (Private Investment in Public Equity) transaction to raise funds but notes no assurance of success or acceptable terms.
• Product Outlook: The company anticipates introducing the "Paradís Vaso Shield" to the marketplace within 90 to 120 days of the filing (by late August/early September 2009).
• Subsequent Events: Following June 30, 2009, the Board approved the issuance of approximately 2,490,000 additional shares to previous investors to adjust their cost basis to $0.50 per share. This is expected to result in an expense of approximately $1,100,000 to be recognized in the quarter ending September 30, 2009.
• Risks: Significant risks include the inability to raise capital, potential dilution of existing shareholders, regulatory delays, and the failure to generate revenue sufficient to cover costs.

Investor Verification Checklist

• Cash Runway: Verify the company's ability to secure funding before mid-September 2009 to avoid insolvency.
• Subsequent Expense: Confirm the impact of the $1.1 million expense related to the subsequent share issuance on the Q3 2009 financials.
• Convertible Debt Terms: Review the conversion terms ($0.50/share) and the potential for significant dilution if the stock price rises above $1.50 or upon maturity.
• Product Launch: Monitor the commercial launch and market acceptance of the "Paradís Vaso Shield" product.
• Registration Rights: Note that certain common stock is classified outside of equity due to registration rights obligations; verify if these have been resolved.